76. 下垂体性ゴナドトロピン分泌亢進症 Pituitary gonadotropin secretion hyperthyroidism Clinical trials / Disease details

臨床試験数 : 29 / 薬物数 : 44 - (DrugBank : 14) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 15

14 trials found

diseases per page:

Showing 1 to 10 of 14 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05341115 (ClinicalTrials.gov)	March 20, 2023	18/4/2022	A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty	An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Le ...	Central Precocious Puberty	Drug: Leuprorelin Acetate Depot 3M	Takeda	NULL	Not yet recruiting	N/A	9 Years	All	80	Phase 4	China
2	NCT03963752 (ClinicalTrials.gov)	August 15, 2019	22/5/2019	Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western ...	Evidence-based Medical Research on the Treatment of Children's Rapid Progressive Central Precocious ...	Idiopathic Precocious Puberty	Drug: Ziyinxiehuo Granules Herbs;Drug: Megestrol Acetate Tablet;Drug: Leuprorelin Acetate3.75mg Injec ...	Children's Hospital of Fudan University	NULL	Recruiting	5 Years	8 Years	Female	164	Phase 4	China
3	NCT03695237 (ClinicalTrials.gov)	October 24, 2018	2/10/2018	A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate45 ...	A Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetic ...	Central Precocious Puberty (CPP)	Drug: Leuprolide Acetate (LA)	AbbVie	NULL	Active, not recruiting	2 Years	11 Years	All	45	Phase 3	United States;Puerto Rico
4	NCT02974270 (ClinicalTrials.gov)	June 2016	19/5/2016	Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate	Analysis of Body Mass Index in Central Precocious Puberty(CPP) Patients Treated With Leuprolide Acet ...	Precocious Puberty, Central	Drug: Leuprolide	Kyungpook National University	NULL	Recruiting	N/A	9 Years	Both	100	Phase 4	Korea, Republic of
5	NCT02811471 (ClinicalTrials.gov)	June 2016	21/6/2016	Pharmacokinetic Study of Leuprolide AcetateInjectable Suspension in the Treatment of Central Precoci ...	An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leupro ...	Central Precocious Puberty	Drug: Leuprolide	Nemours Children's Clinic	Tolmar Inc.	Recruiting	2 Years	9 Years	Both	5	Phase 3	United States
6	NCT02452931 (ClinicalTrials.gov)	August 31, 2015	5/5/2015	Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty	An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leupro ...	Precocious Puberty, Central	Drug: Leuprolide Acetate 45 mg	Tolmar Inc.	NULL	Completed	2 Years	9 Years	All	64	Phase 3	United States;Argentina;Canada;Chile;Mexico;New Zealand
7	NCT03316482 (ClinicalTrials.gov)	June 11, 2015	12/10/2017	Leuprorelin AcetateDPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty ...	A Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of Leuprorelin AcetateDPS ...	Central Precocious Puberty	Drug: Leuplin DPS 11.25mg	Jin Soon Hwang	NULL	Completed	4 Years	9 Years	All	58	Phase 4	Korea, Republic of
8	NCT01634321 (ClinicalTrials.gov)	July 2011	3/7/2012	The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Aceta ...	The Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuproli ...	Central Precocious Puberty	Drug: Luphere depot 3.75mg(Leuprolide acetate 3.75mg)	Daewoong Pharmaceutical Co. LTD.	NULL	Completed	4 Years	9 Years	Both	63	Phase 4	Korea, Republic of
9	NCT00667446 (ClinicalTrials.gov)	December 2008	24/4/2008	Safety Extension Study Of Leuprolide Acetate(Lupron Depot) In The Treatment Of Central Precocious Pu ...	A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate11. ...	Precocious;Leuprolide Acetate;Luteinizing Hormone (LH);Gonadotrophin-releasing Hormone Agonist (GnRH ...	Drug: Leuprolide Acetate 3 Month Depot	AbbVie (prior sponsor, Abbott)	NULL	Completed	N/A	N/A	All	72	Phase 3	United States;Puerto Rico
10	NCT00635817 (ClinicalTrials.gov)	June 2008	7/3/2008	A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Pub ...	A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprol ...	Puberty, Precocious	Drug: Leuprolide acetate 11.25 mg;Drug: Leuprolide acetate 30 mg	Abbott	NULL	Completed	2 Years	11 Years	All	84	Phase 3	United States;Puerto Rico

First Previous1 2Next Last